A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B

Inclusion Criteria:

1. be male with a diagnosis of moderate or severe congenital hemophilia A and/or B
(with or without inhibitors)

2. be 18 years or older, up to and including 75 years of age

3. be capable of understanding and willing to comply with the conditions of the protocol

4. have read, understood and provided written informed consent

Exclusion Criteria:

1. have any coagulation disorder other than hemophilia A or B

2. have a body weight >105 kg (231 lb)

3. be immuno-suppressed (i.e., the patient should not receive systemic immunosuppressive
medication <30 days prior to enrollment, CD4 counts at screening should be >200/µl)

4. have a known allergy or hypersensitivity to rabbits

5. have platelet count <100,000/mL

6. have had within one month prior to first administration of the study drug in this
study a major surgical procedure (e.g. orthopedic, abdominal)

7. have an active, ongoing bleeding for which the patient is being treated, or treatment
for a bleeding was stopped within 24 hours of the time of study drug administration

8. have received a Factor VII or FVIIa containing product (either plasma derived or
recombinant) within 72 hours prior to any study drug administration

9. have received an investigational drug within 30 days of the first study drug
administration, or is expected to receive such drug during participation in this
study

10. have a clinically relevant hepatic (hepatic enzymes >3 times the upper limit of
normal) and/or renal impairment (creatinine >2 times the upper limit of normal)

11. have a history of arterial and/or venous thromboembolic events (such as myocardial
infarction, ischemic strokes, transient ischemic attacks, deep venous thrombosis or
pulmonary embolism) within 2 years prior to first dose of study drug, have an
arterial stent in place or have clinically significant atherosclerotic disease (e.g.,
angina pectoris, peripheral vascular disease)

12. use any anticoagulant for arterial/venous obstructions and/or atrial fibrillation
within 7 days prior to first study drug administration

13. have an active malignancy (those with non-melanoma skin cancer are allowed)

14. have any life-threatening disease or other disease or condition which, according to
the investigator's judgment, could imply a potential hazard to the patient, interfere
with the trial participation or trial outcome